Login to Your Account



Clinic Roundup


Monday, October 8, 2012
• XenoPort Inc., of Santa Clara, Calif., reported Phase I data testing four different oral formulations of XP23829, a fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF) and is in development for relapsing-remitting multiple sclerosis and/or psoriasis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription